AIMS: Monocarboxylate transporters (MCTs) have been considered promising targets for cancer therapy, since they facilitate lactate efflux in glycolytic tumours. However, their role in solid tumours is still poorly understood. Thus, the present work aimed to contribute to understanding the involvement of MCT1 and MCT4 in breast cancer progression as well as MCT regulation by CD147. METHODS AND RESULTS: The expression of the membrane transporters MCT1 and MCT4 was analysed in a series of breast carcinomas (249 cases) and their clinicopathological significance investigated. Additionally, we analysed the significance of CD147 co-expression, as an important regulator of MCT expression and activity. MCT1 was significantly increased in breast carcinomas when compared with normal breast tissue and, importantly, both MCT1 and CD147 were associated with poor prognostic variables such as basal-like subtype and high grade tumours. CONCLUSIONS: These results provide evidence for a prognostic value of MCT1 in breast carcinoma and support the exploitation of the complex MCT1/CD147 as a promising target for cancer therapy, especially in basal-like breast carcinoma.
AIMS: Monocarboxylate transporters (MCTs) have been considered promising targets for cancer therapy, since they facilitate lactate efflux in glycolytic tumours. However, their role in solid tumours is still poorly understood. Thus, the present work aimed to contribute to understanding the involvement of MCT1 and MCT4 in breast cancer progression as well as MCT regulation by CD147. METHODS AND RESULTS: The expression of the membrane transporters MCT1 and MCT4 was analysed in a series of breast carcinomas (249 cases) and their clinicopathological significance investigated. Additionally, we analysed the significance of CD147 co-expression, as an important regulator of MCT expression and activity. MCT1 was significantly increased in breast carcinomas when compared with normal breast tissue and, importantly, both MCT1 and CD147 were associated with poor prognostic variables such as basal-like subtype and high grade tumours. CONCLUSIONS: These results provide evidence for a prognostic value of MCT1 in breast carcinoma and support the exploitation of the complex MCT1/CD147 as a promising target for cancer therapy, especially in basal-like breast carcinoma.
Authors: Stephanos Pavlides; Iset Vera; Ricardo Gandara; Sharon Sneddon; Richard G Pestell; Isabelle Mercier; Ubaldo E Martinez-Outschoorn; Diana Whitaker-Menezes; Anthony Howell; Federica Sotgia; Michael P Lisanti Journal: Antioxid Redox Signal Date: 2011-11-17 Impact factor: 8.401
Authors: Vera Miranda-Gonçalves; Mrinalini Honavar; Céline Pinheiro; Olga Martinho; Manuel M Pires; Célia Pinheiro; Michelle Cordeiro; Gil Bebiano; Paulo Costa; Isabel Palmeirim; Rui M Reis; Fátima Baltazar Journal: Neuro Oncol Date: 2012-12-20 Impact factor: 12.300
Authors: Jennifer M Johnson; Stephen Y Lai; Paolo Cotzia; David Cognetti; Adam Luginbuhl; Edmund A Pribitkin; Tingting Zhan; Mehri Mollaee; Marina Domingo-Vidal; Yunyun Chen; Barbara Campling; Voichita Bar-Ad; Ruth Birbe; Madalina Tuluc; Ubaldo Martinez Outschoorn; Joseph Curry Journal: Semin Oncol Date: 2015-09-24 Impact factor: 4.929